Details for Patent: 10,112,942

Which drugs does patent 10,112,942 protect, and when does it expire?

Patent 10,112,942 protects RETEVMO and is included in two NDAs.

Protection for RETEVMO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and five patent family members in forty countries.

Summary for Patent: 10,112,942

Title:	Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Abstract:	Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
Inventor(s):	Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Tony P. Tang, Li Ren
Assignee:	Array Biopharma Inc
Application Number:	US15/858,240
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 10,112,942

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eli Lilly And Co	RETEVMO	selpercatinib	CAPSULE;ORAL	213246-001	May 8, 2020		RX	Yes	No	10,112,942*PED				Y
Eli Lilly And Co	RETEVMO	selpercatinib	CAPSULE;ORAL	213246-002	May 8, 2020		RX	Yes	Yes	10,112,942*PED				Y
Eli Lilly And Co	RETEVMO	selpercatinib	TABLET;ORAL	218160-001	Apr 10, 2024		RX	Yes	No	10,112,942*PED				Y
Eli Lilly And Co	RETEVMO	selpercatinib	TABLET;ORAL	218160-002	Apr 10, 2024		RX	Yes	No	10,112,942*PED				Y
Eli Lilly And Co	RETEVMO	selpercatinib	TABLET;ORAL	218160-003	Apr 10, 2024		RX	Yes	No	10,112,942*PED				Y
Eli Lilly And Co	RETEVMO	selpercatinib	TABLET;ORAL	218160-004	Apr 10, 2024		RX	Yes	Yes	10,112,942*PED				Y

International Family Members for US Patent 10,112,942

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	109919
Argentina	109920
Australia	2017342022
Australia	2017342027
Brazil	112019007143
Brazil	112019007144
Canada	3039760